Covid-19
Map: The world according to covid vaccine coverage.
12 Nov, 2021 | 10:34h | UTCThe world according to covid vaccine coverage – The BMJ
Commentary on Twitter
A year since the first covid vaccines were announced, rollouts are under way all over the world—to differing degrees.
This map shows the percentage of national population to have received two doses of covid vaccinehttps://t.co/rIU3qeWXIK @munkeatlooi pic.twitter.com/zZHr1XXBe8
— The BMJ (@bmj_latest) November 11, 2021
IDSA Guidelines on Infection Prevention for Healthcare Personnel Caring for Patients with Suspected or Known COVID-19.
11 Nov, 2021 | 09:01h | UTC
Commentary on Twitter
New recommendation on the use of eye protection as well as revised recommendations and literature on the use of PPE now available in IDSA’s COVID-19 Infection Prevention Guideline: https://t.co/MiACvSoG92#COVID19Guidelines pic.twitter.com/Zp7s0Ely9J
— IDSA (@IDSAInfo) November 5, 2021
Podcast | COVID Updates: The Outpatient Edition.
11 Nov, 2021 | 08:57h | UTCCOVID Updates: The Outpatient Edition – The Curbsiders
Commentary on Twitter
Who gets a #COVID booster? Can we mix & match vaccines? What are monoclonal antibodies & when should we use them? Shots for kids? Ready yourself to answer these questions & more w/ @MonicaGandhi9 #vaccine #MedEd #FOAMed https://t.co/URrfwtuxVf pic.twitter.com/o26ElbPNaJ
— The Curbsiders (@thecurbsiders) November 8, 2021
COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.
11 Nov, 2021 | 08:59h | UTCCOVID antiviral pills: what scientists still want to know – Nature
Related:
The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.
Merck to allow other nations to produce new COVID-19 antiviral.
Video: Merck’s Covid pill could transform treatment. Here’s how it works.
How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.
What we know — and don’t know — about Merck’s new Covid-19 pill.
Merck’s Covid-19 pill is great news but may not be a game-changer.
Video | A Pill For COVID? A Doctor Explains Molnupiravir.
M-A: Low vitamin D levels do not aggravate COVID-19 risk or death, and vitamin D supplementation does not improve outcomes in hospitalized patients with COVID-19.
11 Nov, 2021 | 08:53h | UTC
Perspective | COVID’s endgame: Scientists have a clue about where SARS-CoV-2 is headed.
11 Nov, 2021 | 08:55h | UTCCOVID’s endgame: Scientists have a clue about where SARS-CoV-2 is headed – NPR
An Update on Multisystem Inflammatory Syndrome in Children Related to SARS-CoV-2.
11 Nov, 2021 | 08:52h | UTCRelated:
Ten Things to Know About Multisystem Inflammatory Syndrome in Children (MIS-C).
Kawasaki Disease and Multisystem Inflammatory Syndrome in Children: An Overview and Comparison.
Cohort study: Six month follow-up of Multisystem Inflammatory Syndrome in Children.
Clinical Update: Acute covid-19 and multisystem inflammatory syndrome in children
Cutaneous findings in SARS-CoV-2-associated Multisystem Inflammatory Disease in Children (MIS-C)
SR: Multisystem inflammatory syndrome in children related to COVID-19
RCT: Pfizer vaccine shows 90.7% efficacy for preventing Covid-19 in children 5 to 11 years of age.
10 Nov, 2021 | 07:24h | UTC
Commentary on Twitter
In this multi-phase trial, two 10-μg doses of the BNT162b2 vaccine administered 21 days apart were safe, immunogenic, and 90.7% effective against #COVID19 in 5-to-11-year-old children. #Covid19vaccine https://t.co/kuj2eI4YCE pic.twitter.com/BWEkYxn8a0
— NEJM (@NEJM) November 9, 2021
How an outbreak became a pandemic: a chronological analysis of crucial junctures and international obligations in the early months of the COVID-19 pandemic.
10 Nov, 2021 | 07:22h | UTC
Commentary on Twitter
NEW—How an outbreak became a pandemic: an analysis of the early months of #COVID19 by @TheIndPanel.
Authors point to reform & offer a framework for robust future #pandemic preparedness & response. https://t.co/MlW6zXj2Dn @sudhvir pic.twitter.com/rgHu1QggNQ
— The Lancet (@TheLancet) November 9, 2021
French health authority advises against Moderna Covid-19 vaccine for under 30s.
10 Nov, 2021 | 07:18h | UTCFrench Health Authority Advises Against Moderna COVID-19 Vaccine for Under 30s – Reuters
See also: France advises against Moderna for under-30s over rare heart risk – Associated Press
Related: Sweden, Denmark pause Moderna COVID-19 vaccine for younger age groups.
Commentary on Twitter
France's public health authority has recommended people under 30 be given Pfizer's Comirnaty COVID-19 vaccine when available instead of Moderna Inc's Spikevax jab, which carried comparatively higher risks of heart-related problems. https://t.co/4gPTXzEsw0
— Reuters Health (@Reuters_Health) November 9, 2021
A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.
10 Nov, 2021 | 07:13h | UTCOriginal viewpoint: Supercharging New Viral Variants: The Dangers Of Molnupiravir (Part 1) – Forbes
Related:
The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.
Merck to allow other nations to produce new COVID-19 antiviral.
Video: Merck’s Covid pill could transform treatment. Here’s how it works.
How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.
What we know — and don’t know — about Merck’s new Covid-19 pill.
Merck’s Covid-19 pill is great news but may not be a game-changer.
Video | A Pill For COVID? A Doctor Explains Molnupiravir.
Opinion | Protective immunity after recovery from SARS-CoV-2 infection.
10 Nov, 2021 | 07:15h | UTCProtective immunity after recovery from SARS-CoV-2 infection – The Lancet Infectious Diseases
Commentary on Twitter
"Policy makers should consider recovery from previous SARS-CoV-2 infection equal to immunity from vaccination for purposes related to entry to public events, businesses, and the workplace,or travel requirements"
Do you agree with this?
I don't #IDtwitter https://t.co/FHbgXILD8Z— Antibiotic Stewa®️x? Bassam Ghanem (@ABsteward) November 9, 2021
Practice Review: COVID-19 rapid diagnostics.
9 Nov, 2021 | 01:52h | UTCCOVID-19 rapid diagnostics: practice review – Emergency Medicine Journal
Provocative study suggests that persistent physical symptoms after COVID-19 infection may be associated more with the belief in having been infected with SARS-CoV-2 than with having laboratory-confirmed COVID-19 infection.
9 Nov, 2021 | 01:46h | UTCAuthor Interview: Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Results With Persistent Physical Symptoms – JAMA Internal Medicine
Related:
Update to post-acute sequelae of SARS-CoV-2 infection: Caring for the ‘long-haulers’.
Systematic Review: Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection.
WHO Consensus: A clinical case definition of post COVID-19 condition (Long Covid).
Characterizing long COVID: a living systematic review.
Long Covid – The illness narratives.
New guidelines to help doctors manage long COVID patients published.
M-A: More than 50 long-term effects of COVID-19. (several articles on the subject)
Commentary on Twitter
Except for anosmia, persistent symptoms after COVID-19 may be more related to the belief of having had #COVID19 than to actual SARS-Co-V2 infection. Clinicians and researchers should also consider general mechanisms that may not be specific to #SARSCoV2 https://t.co/IdSh5GhdQ6
— JAMA Internal Medicine (@JAMAInternalMed) November 8, 2021
How protein-based COVID vaccines could change the pandemic.
9 Nov, 2021 | 01:41h | UTCHow protein-based COVID vaccines could change the pandemic – Nature
We can be confident there have been far more than 5 million global Covid deaths – “Estimating ‘excess’ fatalities, a more robust analysis method, puts the pandemic’s grim toll between 10m and 19m people”.
9 Nov, 2021 | 01:43h | UTCWe can be confident there have been far more than 5 million global Covid deaths – The Guardian
Related:
Global Covid-19 deaths surpass five million.
Under-reporting of deaths limits our understanding of true burden of covid-19.
Study shows COVID-19 has caused the biggest decrease in life expectancy since World War II.
Just how do deaths due to COVID-19 stack up?
Exploring the gap between excess mortality and COVID-19 deaths in 67 countries.
COVID-19 has caused 6.9 million deaths globally, more than double what official reports show
Regional lymphadenopathy following COVID-19 vaccination: Literature review and considerations for patient management in breast cancer care.
9 Nov, 2021 | 01:44h | UTCRelated:
2 Case Series and Guidance | Lymphadenopathy in COVID-19 Vaccine Recipients
Not all Covid waves look the same. Here’s a snapshot of the Delta surge.
9 Nov, 2021 | 01:28h | UTCNot all Covid waves look the same. Here’s a snapshot of the Delta surge – STAT
Commentary on Twitter
If you know someone on the fence about vaccination, show them this https://t.co/ndPLhpLlh4 pic.twitter.com/L6RLwHyGCi
— David Juurlink (@DavidJuurlink) November 8, 2021
Nose sprays, needle-free patches, durable immunity: towards the next generation of COVID vaccines.
9 Nov, 2021 | 01:31h | UTC
[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.
7 Nov, 2021 | 20:35h | UTCCommentaries:
Pfizer’s Good News Is the World’s Good News – Science
Experimental Pfizer pill prevents Covid hospitalizations and deaths – STAT
Pfizer reports good results against severe COVID-19 for its antiviral pill – CIDRAP
Covid: Pfizer says antiviral pill 89% effective in high-risk cases – BBC
Pfizer says COVID-19 pill cut hospital, death risk by 90% – Associated Press
Commentary on Twitter (thread – click for more)
Pfizer’s oral protease inhibitor PF-07321332 for #COVID19 Reduced Risk of Hospitalization or Death from 6.7% (41/612) to 1.0% (6/607) when starting within 5 days of symptom onset.
10 vs 0 deaths. #idtwitter https://t.co/ZAIm6Y5mAt— David Boulware, MD MPH (@boulware_dr) November 5, 2021
Myocarditis Following COVID-19 mRNA Vaccine: A Case Series and Incidence Rate Determination.
7 Nov, 2021 | 20:29h | UTCRelated:
Heart-inflammation risk from Pfizer COVID vaccine is very low.
Viewpoint | Pediatric COVID-19 Vaccines: What Parents, Practitioners, and Policy Makers Need to Know.
7 Nov, 2021 | 20:31h | UTCPediatric COVID-19 Vaccines: What Parents, Practitioners, and Policy Makers Need to Know – JAMA
Viewpoint | Children and COVID-19 in schools.
7 Nov, 2021 | 20:24h | UTCChildren and COVID-19 in schools – Science
Related:
Instead of quarantine for Covid-exposed students, some schools are trying test-to-stay.
Opinion | Data from routine Covid testing can help schools stay open this year.
CDC Report: Schools without mask requirements were more likely to have Covid-19 outbreaks.
Perspective | Schools have begun mass testing for COVID-19. But hurdles and uncertainties remain.
COVID and schools: the evidence for reopening safely.
COVID studies note online learning stress, fewer cases in schools with protocols
[Not published yet] Chinese drug firm Sinovac says Covid-19 vaccine safe for children and babies as young as six months old.
7 Nov, 2021 | 20:32h | UTCRelated:
COVID-19 vaccination in pregnancy, pediatrics, immunocompromised patients, and persons with history of allergy or prior SARS-CoV-2 infection: overview of current recommendations and pre- and post-marketing evidence for vaccine efficacy and safety.
7 Nov, 2021 | 20:27h | UTC